Stephen M. Simes, president and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will give two presentations at the BIO International Convention in San Diego, California, the week of June 16, 2008. The BIO International Convention (BIO) is a symposium including leading pharmaceutical and biotechnology companies presenting to institutional investors, portfolio managers, analysts, and the media, to discuss emerging trends in the sector.
Mr. Simes will discuss, on Tuesday, June 17, 2008 at 3:45 PDT, the LibiGel® (testosterone gel) clinical development plan and recent primary research data indicating the potential size of the U.S. market for BioSante’s LibiGel in the treatment of female sexual dysfunction. Mr. Simes also will comment on the recent engagement of Deutsche Bank as BioSante’s strategic advisor.
Additionally, on Wednesday, June 18, 2008 from 10-11 AM PDT, Mr. Simes will present and discuss a poster entitled, “LibiGel® Treatment of Women with Hypoactive Sexual Desire Disorder (HSDD): A Clear Path to Approval.”
“We are delighted to have the opportunity to participate at this year’s BIO Convention,” said Mr. Simes. “It is particularly rewarding for us to be able to offer two presentations surrounding various aspects of LibiGel®, the lead drug candidate for the treatment of female sexual dysfunction in menopausal women, during this prestigious event.”
About BIO
The Biotechnology Industry Organization is a trade association that hosts the BIO International Convention. The net proceeds of the event support BIO's activities throughout the year. BIO is the champion of biotechnology and the advocate for its member organizations – both large and small.
BIO is the world’s largest biotechnology organization, providing advocacy, business development, and communications services for more than 1,150 members worldwide. Corporate members range from entrepreneurial companies in the process of developing a first product to Fortune 100 multinationals. BIO also represents state and regional biotech associations, academic centers, and service providers to the industry.
Since BIO was formed in 1993, the biology-based, entrepreneurial industry has grown from a small number of companies concentrated in a few cities to an industry that increasingly extends throughout society. Nearly every state courts biotechnology development, as do an increasing number of countries around the world.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: www.biosantepharma.com.
Contacts:
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
or
Investor
Relations:
The Investor Relations Group
Investors:
Adam
S. Holdsworth / Erica Ruderman
212-825-3210
or
Media:
Laura
Colontrelle / Janet Vasquez
212-825-3210
